Pembrolizumab in HER2-Positive Gastric Cancer

Cited 5 times in

Authors: Yelena Y Janjigian ; Akihito Kawazoe ; Yuxian Bai ; Jianming Xu ; Sara Lonardi ; Jean Phillipe Metges ; Patricio Yañez ; Lucjan S Wyrwicz ; Lin Shen ; Yuriy Ostapenko ; Mehmet Bilici ; Hyun Cheol Chung ; Kohei Shitara ; Shukui Qin ; Eric Van Cutsem ; Josep Tabernero ; Suxia Luo ; Mauricio Mahave ; Yong Tang ; Maeve Lowery ; Maria M F Monteiro ; Linzhi Xu ; Chie-Schin Shih ; Kanu P Sharan ; Pooja Bhagia ; Sun Young Rha

MeSH: Adenocarcinoma* / drug therapy ; Adenocarcinoma* / mortality ; Adenocarcinoma* / pathology ; Aged ; Antibodies, Monoclonal, Humanized* / therapeutic use ; Antineoplastic Agents, Immunological* / adverse effects ; Antineoplastic Agents, Immunological* / therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; Double-Blind Method ; Esophagogastric Junction / pathology ; Female ; Humans ; Male ; Middle Aged ; Progression-Free Survival ; Receptor, ErbB-2* / analysis ; Receptor, ErbB-2* / metabolism ; Stomach Neoplasms* / drug therapy ; Stomach Neoplasms* / mortality ; Stomach Neoplasms* / pathology ; Trastuzumab / therapeutic use

Appears in Collections:: 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

Show full item record

YUHSpace: Pembrolizumab in HER2-Positive Gastric Cancer